14 Nov 2026
NEWS · CONTEXT · PERSPECTIVE
English

News in perspective.
Context. Clarity. Sources.

Hot topics, news and trends shaping the world

Health Canada warns of contaminated injectable drugs after seizing over 11,400 vials

The November 6 advisory names unauthorized peptide products and two Canadian sellers, and urges users with signs of infection to seek urgent medical care.

Editorial policy

Health Canada photograph of seized injectable vials in an ivory paper collage with a microscope drawing and warning details
Health Canada product photograph.red. Advisory dated November 6, 2026.

Health Canada has warned consumers against unauthorized injectable peptides after laboratory tests detected bacteria in products supplied by Shanghai ERP Peptide Biotechnology. More than 11,400 vials were seized from the supplier and two Canadian online retailers.

The November 6 advisory names truenorthbiolabs.ca and bcaxiompeptide.com. Officials obtained court-issued entry warrants, seized unauthorized drugs and took enforcement action; the websites are no longer active.

Examples listed include hCG, MOTS-C, NAD+, retatrutide, tesamorelin and tirzepatide. The warning concerns unauthorized products: consumers should check the specific product’s authorization rather than assume a substance name establishes its safety.

Testing found Acinetobacter seifertii, Acinetobacter nosocomialis and Cutibacterium acnes. Health Canada says contaminated injections can cause serious infections, hospitalization or life-threatening sepsis.

What consumers should do

Do not buy or use the unauthorized products. Anyone who has used them and develops fever, redness, swelling, injection-site pain or feels unwell should seek medical attention immediately.

Buy prescription medicines from licensed pharmacies and check for an eight-digit Drug Identification Number. Products labelled for research rather than human consumption should not be injected.

Sources

  1. Health Canada warns about contaminated unauthorized injectable peptides and non-peptide drugs — Health Canada
Assigned writer
Amelia JohnsonCredit pending confirmation
Assigned reviewer
Oliver SmithReview pending

Published